{"nctId":"NCT03725033","briefTitle":"Clinical Trial of Efficacy and Safety of Subetta in the Treatment of Impaired Glucose Tolerance","startDateStruct":{"date":"2018-10-10","type":"ACTUAL"},"conditions":["Impaired Glucose Tolerance"],"count":538,"armGroups":[{"label":"Subetta","type":"EXPERIMENTAL","interventionNames":["Drug: Subetta"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Subetta","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Outpatients aged 18 to 70 years.\n2. Impaired glucose tolerance (plasma glucose from 7.8 to 11.0 mmol / L 2 hours after a 75 g oral glucose consumption during an oral glucose tolerance test, while fasting plasma glucose \\<7.0 mmol / L).\n3. HbA1c is 5.7-6.4%.\n4. The body mass index is 25.0-39.9 kg / m\\^2.\n5. Consent to use reliable contraceptive methods during the study (for men and women with reproductive potential).\n6. The presence of the signed informed consent form to participate in the clinical trial.\n\nExclusion Criteria:\n\n1. Type 1 or type 2 diabetes.\n2. Use of any medications indicated in the section \"Prohibited concomitant medications\".\n3. Acute or exacerbation / decompensation of a chronic disease of any etiology at the time of the examination or during the previous week.\n4. Uncontrolled arterial hypertension with blood pressure: systolic blood pressure \\> 160 mm Hg and/or diastolic blood pressure \\> 110 mm Hg.\n5. Acute coronary syndrome, myocardial infarction, acute impairment of cerebral circulation during the previous 6 months prior to enrollment.\n6. Unstable or life-threatening arrhythmia during the previous 3 months prior to enrollment.\n7. Acute and chronic heart failure with functional class III or IV (according to the classification of the New York Heart Association, 1964).\n8. Respiratory failure.\n9. Chronic kidney disease (classes C3-5 A3).\n10. Hepatic insufficiency (class C according to Child-Pugh).\n11. Presence or suspicion of oncology disease.\n12. The presence of an allergy / hypersensitivity to any component of the medication administered during the treatment.\n13. Alcohol consumption \\> 2 alcohol units for males and \\> 1 alcohol unit for females per day.\n14. Mental illness or drug abuse in anamnesis.\n15. Bariatric surgery in anamnesis, any surgery for 3 months before enrollment.\n16. Pregnancy, breast-feeding; childbirth less than 3 months before enrollment.\n17. Participation in other clinical trials for 3 months before enrollment in this study.\n18. Patients who are related to any of the on-site research personnel directly involved in the conduct of the trial or are an immediate relative of the study investigator. 'Immediate relative' means husband, wife, parent, son, daughter, brother, or sister (regardless of whether they are natural or adopted).\n19. Patients who work for MATERIA MEDICA HOLDING (i.e. the company's employees, temporary contract workers, appointed officials responsible for carrying out the research or immediate relatives of the aforementioned).","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change 2-hour Plasma Glucose (During Oral Glucose Tolerance Test).","description":"Based on medical records. For oral glucose tolerance test, the subject is given 75 g of oral glucose and blood sample is taken 2 hours later. All analysis will be done in a central laboratory.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.27","spread":"0.88"},{"groupId":"OG001","value":"9.11","spread":"0.86"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.28","spread":"2.07"},{"groupId":"OG001","value":"8.32","spread":"2.44"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.99","spread":"2.21"},{"groupId":"OG001","value":"-0.79","spread":"2.55"}]}]}]},{"type":"SECONDARY","title":"Percentage of Patients With 2-hour Plasma Glucose <7.8 mmol / L.","description":"Based on medical records.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"46","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose.","description":"Based on medical records. Fasting plasma glucose is measured after fasting or not eating anything for at least 8 hours.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.83","spread":"0.62"},{"groupId":"OG001","value":"5.88","spread":"0.60"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.01","spread":"1.17"},{"groupId":"OG001","value":"6.02","spread":"0.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.18","spread":"1.25"},{"groupId":"OG001","value":"0.14","spread":"1.06"}]}]}]},{"type":"SECONDARY","title":"Change in HbA1c","description":"Based on medical records. HbA1c is determined by the method certified in accordance with National Glycohemoglobin Standardization Program and standardized in compliance with the reference values adopted in the Diabetes Control and Complications Trial.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"5.9","spread":null},{"groupId":"OG001","value":"6.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.8","spread":null},{"groupId":"OG001","value":"5.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.1","spread":null},{"groupId":"OG001","value":"-0.1","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":105},"commonTop":["Diabetes mellitus","Acute respiratory tract infection","Increase of blood pressure","Headache","Vomiting"]}}}